vs
福尼克斯（PLAB）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
福尼克斯的季度营收约是再鼎医药的1.7倍（$210.4M vs $127.1M），再鼎医药同比增速更快（17.1% vs -5.5%），福尼克斯自由现金流更多（$25.2M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs -3.8%）
福尼克斯是美国半导体光掩模制造商，2009年时位居全球第三大光掩模供应商，同时也是电子束产业倡议组织的成员，专注于为半导体行业提供关键的掩模产品，支撑芯片制造环节的图形转移需求。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
PLAB vs ZLAB — 直观对比
营收规模更大
PLAB
是对方的1.7倍
$127.1M
营收增速更快
ZLAB
高出22.6%
-5.5%
自由现金流更多
PLAB
多$51.9M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
-3.8%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $210.4M | $127.1M |
| 净利润 | $22.9M | — |
| 毛利率 | 33.7% | 51.0% |
| 营业利润率 | 22.9% | -54.6% |
| 净利率 | 10.9% | — |
| 营收同比 | -5.5% | 17.1% |
| 净利润同比 | -32.4% | — |
| 每股收益（稀释后） | $0.39 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLABZLAB
| Q4 25 | — | $127.1M | ||
| Q3 25 | $210.4M | $115.4M | ||
| Q2 25 | $211.0M | $109.1M | ||
| Q1 25 | $212.1M | $105.7M | ||
| Q4 24 | $222.6M | $108.5M | ||
| Q3 24 | $211.0M | $101.8M | ||
| Q2 24 | $217.0M | $100.1M | ||
| Q1 24 | $216.3M | $87.1M |
净利润PLABZLAB
| Q4 25 | — | — | ||
| Q3 25 | $22.9M | $-36.0M | ||
| Q2 25 | $8.9M | $-40.7M | ||
| Q1 25 | $42.9M | $-48.4M | ||
| Q4 24 | $33.9M | — | ||
| Q3 24 | $34.4M | $-41.7M | ||
| Q2 24 | $36.3M | $-80.3M | ||
| Q1 24 | $26.2M | $-53.5M |
毛利率PLABZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | 33.7% | 59.5% | ||
| Q2 25 | 36.9% | 60.6% | ||
| Q1 25 | 35.6% | 63.6% | ||
| Q4 24 | 37.0% | 61.5% | ||
| Q3 24 | 35.6% | 64.1% | ||
| Q2 24 | 36.5% | 64.9% | ||
| Q1 24 | 36.6% | 61.4% |
营业利润率PLABZLAB
| Q4 25 | — | -54.6% | ||
| Q3 25 | 22.9% | -42.3% | ||
| Q2 25 | 26.4% | -50.3% | ||
| Q1 25 | 24.6% | -53.3% | ||
| Q4 24 | 25.1% | -62.6% | ||
| Q3 24 | 24.7% | -66.6% | ||
| Q2 24 | 25.8% | -76.0% | ||
| Q1 24 | 26.6% | -80.7% |
净利率PLABZLAB
| Q4 25 | — | — | ||
| Q3 25 | 10.9% | -31.2% | ||
| Q2 25 | 4.2% | -37.3% | ||
| Q1 25 | 20.2% | -45.8% | ||
| Q4 24 | 15.2% | — | ||
| Q3 24 | 16.3% | -40.9% | ||
| Q2 24 | 16.7% | -80.2% | ||
| Q1 24 | 12.1% | -61.4% |
每股收益（稀释后）PLABZLAB
| Q4 25 | — | $-0.05 | ||
| Q3 25 | $0.39 | $-0.03 | ||
| Q2 25 | $0.15 | $-0.04 | ||
| Q1 25 | $0.68 | $-0.04 | ||
| Q4 24 | $0.54 | $-0.09 | ||
| Q3 24 | $0.55 | $-0.04 | ||
| Q2 24 | $0.58 | $-0.08 | ||
| Q1 24 | $0.42 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $575.8M | $689.6M |
| 总债务越低越好 | $16.0K | — |
| 股东权益账面价值 | $1.1B | $715.5M |
| 总资产 | $1.8B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资PLABZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | $575.8M | $717.2M | ||
| Q2 25 | $558.4M | $732.2M | ||
| Q1 25 | $642.2M | $757.3M | ||
| Q4 24 | $640.7M | $779.7M | ||
| Q3 24 | $606.4M | $616.1M | ||
| Q2 24 | $559.9M | $630.0M | ||
| Q1 24 | $521.5M | $650.8M |
总债务PLABZLAB
| Q4 25 | — | — | ||
| Q3 25 | $16.0K | — | ||
| Q2 25 | $19.0K | — | ||
| Q1 25 | $21.0K | — | ||
| Q4 24 | $25.0K | — | ||
| Q3 24 | $28.0K | — | ||
| Q2 24 | $2.5M | — | ||
| Q1 24 | $2.7M | — |
股东权益PLABZLAB
| Q4 25 | — | $715.5M | ||
| Q3 25 | $1.1B | $759.9M | ||
| Q2 25 | $1.1B | $791.7M | ||
| Q1 25 | $1.1B | $810.8M | ||
| Q4 24 | $1.1B | $840.9M | ||
| Q3 24 | $1.1B | $667.7M | ||
| Q2 24 | $1.0B | $704.2M | ||
| Q1 24 | $1.0B | $762.2M |
总资产PLABZLAB
| Q4 25 | — | $1.2B | ||
| Q3 25 | $1.8B | $1.2B | ||
| Q2 25 | $1.7B | $1.2B | ||
| Q1 25 | $1.7B | $1.2B | ||
| Q4 24 | $1.7B | $1.2B | ||
| Q3 24 | $1.6B | $985.3M | ||
| Q2 24 | $1.6B | $987.4M | ||
| Q1 24 | $1.6B | $988.4M |
负债/权益比PLABZLAB
| Q4 25 | — | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $50.1M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $25.2M | $-26.7M |
| 自由现金流率自由现金流/营收 | 12.0% | -21.0% |
| 资本支出强度资本支出/营收 | 11.8% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.19× | — |
| 过去12个月自由现金流最近4个季度 | $64.5M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流PLABZLAB
| Q4 25 | — | $-26.0M | ||
| Q3 25 | $50.1M | $-32.0M | ||
| Q2 25 | $31.5M | $-31.0M | ||
| Q1 25 | $78.5M | $-61.7M | ||
| Q4 24 | $68.4M | $-55.8M | ||
| Q3 24 | $75.1M | $-26.8M | ||
| Q2 24 | $76.5M | $-42.2M | ||
| Q1 24 | $41.5M | $-90.1M |
自由现金流PLABZLAB
| Q4 25 | — | $-26.7M | ||
| Q3 25 | $25.2M | $-35.0M | ||
| Q2 25 | $-29.1M | $-33.9M | ||
| Q1 25 | $43.3M | $-63.2M | ||
| Q4 24 | $25.2M | $-58.4M | ||
| Q3 24 | $50.7M | $-28.2M | ||
| Q2 24 | $56.5M | $-42.9M | ||
| Q1 24 | $-1.8M | $-91.1M |
自由现金流率PLABZLAB
| Q4 25 | — | -21.0% | ||
| Q3 25 | 12.0% | -30.4% | ||
| Q2 25 | -13.8% | -31.1% | ||
| Q1 25 | 20.4% | -59.9% | ||
| Q4 24 | 11.3% | -53.8% | ||
| Q3 24 | 24.0% | -27.7% | ||
| Q2 24 | 26.0% | -42.9% | ||
| Q1 24 | -0.8% | -104.5% |
资本支出强度PLABZLAB
| Q4 25 | — | 0.5% | ||
| Q3 25 | 11.8% | 2.6% | ||
| Q2 25 | 28.7% | 2.6% | ||
| Q1 25 | 16.6% | 1.5% | ||
| Q4 24 | 19.4% | 2.4% | ||
| Q3 24 | 11.6% | 1.3% | ||
| Q2 24 | 9.2% | 0.7% | ||
| Q1 24 | 20.0% | 1.1% |
现金转化率PLABZLAB
| Q4 25 | — | — | ||
| Q3 25 | 2.19× | — | ||
| Q2 25 | 3.55× | — | ||
| Q1 25 | 1.83× | — | ||
| Q4 24 | 2.02× | — | ||
| Q3 24 | 2.18× | — | ||
| Q2 24 | 2.11× | — | ||
| Q1 24 | 1.59× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLAB
| High End Integrated Circuits | $53.6M | 25% |
| High End Flat Panel Displays | $53.5M | 25% |
| KR | $43.7M | 21% |
| Other | $42.1M | 20% |
| Mainstream Flat Panel Displays | $9.1M | 4% |
| Transferred At Point In Time | $8.4M | 4% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
